Teva Pharmaceutical Industries Stock Short Ratio
| TEV Stock | EUR 21.20 0.70 3.41% |
Teva Pharmaceutical Industries fundamentals help investors to digest information that contributes to Teva Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Teva Stock. The fundamental analysis module provides a way to measure Teva Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Teva Pharmaceutical stock.
Teva |
Teva Pharmaceutical Industries Company Short Ratio Analysis
Teva Pharmaceutical's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Based on the latest financial disclosure, Teva Pharmaceutical Industries has a Short Ratio of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Drug Manufacturers - Specialty & Generic industry. The short ratio for all Germany stocks is 100.0% higher than that of the company.
Did you try this?
Run Global Correlations Now
Global CorrelationsFind global opportunities by holding instruments from different markets |
| All Next | Launch Module |
Teva Fundamentals
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 | |||
| Profit Margin | (0.16) % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 28.17 B | |||
| Shares Outstanding | 1.11 B | |||
| Shares Owned By Insiders | 2.00 % | |||
| Shares Owned By Institutions | 49.70 % | |||
| Price To Book | 1.16 X | |||
| Price To Sales | 0.61 X | |||
| Revenue | 14.93 B | |||
| Gross Profit | 6.97 B | |||
| EBITDA | (827 M) | |||
| Net Income | (2.35 B) | |||
| Cash And Equivalents | 1.97 B | |||
| Cash Per Share | 1.81 X | |||
| Total Debt | 19.1 B | |||
| Debt To Equity | 184.30 % | |||
| Current Ratio | 0.96 X | |||
| Book Value Per Share | 7.11 X | |||
| Cash Flow From Operations | 1.59 B | |||
| Earnings Per Share | (1.96) X | |||
| Price To Earnings To Growth | 0.75 X | |||
| Target Price | 11.47 | |||
| Number Of Employees | 34 K | |||
| Beta | 1.22 | |||
| Market Capitalization | 10.47 B | |||
| Total Asset | 44.01 B | |||
| Five Year Return | 3.24 % | |||
| Net Asset | 44.01 B |
About Teva Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Teva Pharmaceutical Industries's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Teva Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Teva Pharmaceutical Industries based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Teva Stock
Teva Pharmaceutical financial ratios help investors to determine whether Teva Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Teva with respect to the benefits of owning Teva Pharmaceutical security.